Lonza Group AG L (0QNO)

London
Currency in CHF
566.20
-11.60(-2.01%)
Real-time Data
0QNO Scorecard
Full Analysis
Management has been aggressively buying back shares
Earnings results expected in 8 days
Fair Value
Day's Range
561.60567.20
52 wk Range
361.50589.00
Key Statistics
Edit
Bid/Ask
550.80 / 551.40
Prev. Close
577.8
Open
561.6
Day's Range
561.6-567.2
52 wk Range
361.5-589
Volume
1.19K
Average Volume (3m)
26.44K
1-Year Change
53.57%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0QNO Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Lonza Group AG Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Compare 0QNO to Peers and Sector

Metrics to compare
0QNO
Peers
Sector
Relationship
P/E Ratio
71.0x25.5x−0.6x
PEG Ratio
−1.46−0.290.00
Price/Book
4.4x3.1x2.6x
Price / LTM Sales
6.1x4.2x3.1x
Upside (Analyst Target)
-18.1%54.6%
Fair Value Upside
Unlock7.6%7.7%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 7.92
Dividend Yield
0.72%
Industry Median 0.22%
Annualised payout
4
Paid unevenly
5-Years Growth
+7.78%
Growth Streak

Earnings

Latest Release
Nov 29, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

36.405
FREG
+0.07%
78.44
ALCC
+0.59%
230.350
DB1Gn
+0.33%
40.730
FER
+0.22%
109.30
ENX
+0.37%

FAQ

What Is the Lonza Group (0QNO) Stock Price Today?

The Lonza Group stock price today is 566.20

What Stock Exchange Does Lonza Group Trade On?

Lonza Group is listed and trades on the London stock exchange.

What Is the Stock Symbol for Lonza Group?

The stock symbol for Lonza Group is "0QNO."

Does Lonza Group Pay Dividends? What’s The Current Dividend Yield?

The Lonza Group AG dividend yield is 0.36%.

What Is the Lonza Group Market Cap?

As of today, Lonza Group market cap is 40.88B.

What is Lonza Group Earnings Per Share?

The Lonza Group EPS is 7.92.

What Is the Next Lonza Group Earnings Date?

Lonza Group will release its next earnings report on 29 Jan 2025.

From a Technical Analysis Perspective, Is 0QNO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.